Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 6:33 PM
Ignite Modification Date:
2025-12-24 @ 6:33 PM
NCT ID:
NCT05424757
Eligibility Criteria:
Group 1: Children who do not have bowel or nervous system disease, or neuropsychiatric symptoms.
Inclusion criteria:
Children less than 17 years old who have been taking PEG 3350 for at least one month.
Dose of PEG 3350 greater than or equal to 0.4 grams/kg/day currently recommended by the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) and European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) guidelines (2). Preferences will be given to children taking at least 17 grams/day.
Normal Physical and neurological development for age. Weight and height percentiles ≥ 5% and ≤ 95% for age.
Exclusion criteria:
Children with underlying bowel problems that might be expected to increase bowel permeability (are included in group 2). In this group we will specifically exclude children with:
Diarrhea within the past month. Note that PEG 3350 may cause loose stool and this is often the intended therapeutic effect. Therefore, we will exclude children with presumed infectious diarrhea since this may alter gut permeability but will include children whose loose stool is attributed to PEG 3350. If loose or watery stool began after initiation of PEG 3350 or after an increase in PEG 3350 dose within prior 3 days, children may be enrolled for GROUP 1.
Children whose stool had a recognized diarrhea causing pathogen within the past 4 months will be excluded since the time required to repair epithelial lining is not clear. Enteric pathogens that would prevent enrollment include Salmonella, Shigella, Campylobacter, Yersinia, E. Coli (enterotoxigenic, enteropathogenic, enteraggregative, enterohemorrhagic), Clostridum difficile, Rotavirus, Norovirus, Astrovirus, and other known or suspected diarrhea causing organisms.
H. pylori infection since this causes a stomach inflammation. HIV infection since this may alter bowel permeability (17) and predispose to other types of infection Symptoms neurologic disease or dysfunction (since they will be enrolled in Group 3).
Group 2: Children with problems that might increase intestinal epithelial permeability.
Inclusion criteria:
Children less than 17 years old who have been taking PEG 3350 for at least one month.
Dose of PEG 3350 greater than or equal to 0.4 grams/kg/day currently recommended by the NASPGHAN and ESPGHAN guidelines (2). Preferences will be given to children taking at 17 grams/day.
c. Any of the following problems associated with increased bowel permeability:
* Weight ≤ 5% for age. Malnutrition is associated with increased intestinal permeability.
* Children who had a pathogen (see Group 1 Exclusion Criteria "A. b." for list of pathogens) isolated from their stool within the past month.
* Children with celiac disease who are untreated or began treatment within the past 3 months.
* Children with inflammatory bowel disease
* Children with Hirschsprung disease. This intestinal motility disorder predisposes to bowel injury called enterocolitis (18-20).
* Children with intestinal motility disorders other than Hirschsprung disease.
Exclusion criteria:
a. Children with neurologic or neuropsychiatric symptoms. These children will be enrolled in Group 3.
Group 3: Children with underlying neurologic disease or with neuropsychiatric disorders or symptoms.
Inclusion criteria:
Children less than 17 years old who have been taking PEG 3350 for at least one month.
Dose of PEG 3350 greater than or equal to 0.4 grams/kg/day currently recommended by the NASPGHAN and ESPGHAN guidelines (2). Preference will be given to children taking at least 17 grams/day.
Any of the following problems with the nervous system:
* Diagnosed with a disease that affects nervous system function before starting PEG 3350.
* Diagnosed with a disease that affects nervous system function after starting PEG 3350.
* Abnormal nervous system function without a specific diagnosis.
* Episodic nervous system dysfunction. This might include seizure disorder, metabolic disease, or mitochondrial disease.
Note: Included in Group 3 are children with cerebral palsy, neuronal migration defects, traumatic brain injury, hypoxic ischemic encephalopathy, seizure disorder, tics, migraine, clinical depression, anxiety disorder, obsessive-compulsive disorder, post-surgical brain injury, autism spectrum disorder as well as genetic defects that affect the nervous system (Cornelia de Lange, Rett Syndrome, Pelizaeus-Merzbacher disease, etc.).
Any weight and height (i.e., no exclusions based on growth percentiles). Abnormalities in any organ including the bowel are acceptable.
Exclusion criteria:
a. There are no specific exclusion criteria. This is important since this group may be at the highest risk for PEG 3350 side effects.
Group 4: Children who are not taking PEG 3350. We will enroll 75 children who are not taking PEG 3350. Inclusion and exclusion criteria for these children will be the same as those detailed above for children who are taking PEG 3350 except that they may not have taken PEG 3350 within the last month.
Enrollment targets for Groups 1, 2 and 3:
1. 15 children taking PEG 3350, age 0-6 years old (for each Group).
2. 6 children taking PEG 3350, age 7-12 years old (for each Group).
3. 4 children taking PEG 3350, age 13-17 years old (for each Group).
4. An equal number of children in each age group who are not taking PEG 3350.
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
0 Years
Maximum Age:
16 Years
Study:
NCT05424757
Study Brief:
Protocol Section:
NCT05424757